A daily dose of blarcamesine restored autophagy among patients with early Alzheimer’s disease, with improved outcomes through ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

The obesity market still only has two clear leaders with approved GLP-1 medications, and frontrunners Eli Lilly and Novo ...

Over the past five years, Eli Lilly stock has risen roughly 320% as of market close Aug. 11. Meanwhile, the company has delivered a dividend-adjusted total return of roughly 347% over the last five ...

Kinder Morgan benefits from this through a massive $9.3 billion backlog, with $1.3 billion in new projects added and $750 ...

Eli Lilly had profit of $10 billion in 2024. It could afford its Wisconsin project without Evers' $100 million tax credits ...

Packaged breads and refined grain products may increase the odds of developing IBD, while minimally processed fresh bread and ...

Eli Lilly and Company and the UK Government have announced a joint programme to develop innovative models of care for obesity ...

The Government has joined forces with the pharmaceutical giant that makes weight loss jab Mounjaro in a bid to tackle obesity ...

Leaders at Eli Lilly believe heavy investment in the company's manufacturing footprint “sets a high standard that newcomers ...

Prices for Indian consumers are expected to come down significantly from the current Rs 17,000-Rs 26,000 monthly.

A new daily pill for obesity, orforglipron, has shown promising results in a major clinical trial, helping patients lose ...